Effect of Indication Based Blood Product Transfusion in Patients Undergoing Major Oncological Surgery

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Nov 2, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of different blood transfusion practices in patients undergoing major surgery for pelvic or spinal tumors. Specifically, the researchers want to find out whether giving blood based on how much blood a patient loses during surgery or based on their hemoglobin levels (a measure of the oxygen-carrying protein in blood) leads to better outcomes after surgery. The goal is to see if one method causes fewer complications for patients after surgery.

To be eligible for this trial, participants need to be between 18 and 70 years old, have a pelvic or spinal tumor, and be scheduled for open surgery to remove the tumor that lasts longer than 3 hours with an expected blood loss of over 400 milliliters. Unfortunately, patients outside this age range, those with certain types of tumors, or those who have received specific treatments before surgery cannot participate. If you join the trial, you'll be monitored closely during and after your surgery to help the researchers understand how these different transfusion methods affect your recovery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age between 18 and 70
• • patients with pelvic or spinal tumor
• • conduct open resection surgery for tumor removal
• • with expected surgery duration greater than 3 hours
• • with expected blood loss greater than 400 ml
• Exclusion Criteria:
• • age \< 18 or \>70
• • Limb tumor patients or patients with pelvic and spinal tumors undergoing closed internal fixation or vertebroplasty or minimally invasive surgery
• • received chemotherapy or immunotherapy before surgery
• • with expected surgery length less than 3 hours
• • with expected intraoperative blood loss less than 400ml